Arcturus Therapeutics To Present At Canaccord Annual Growth Conference August 11

mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

Arcturus Therapeutics shares are trading higher. The company announced it will present data on ARCT-810 mRNA therapy in Ornithine Transcarbamylase Deficiency at the 2026 SSIEM Annual Symposium.

8-K filing — Arcturus Therapeutics Holdings Inc. (ARCT)

Filed: 2026-08-25 AccNo: 0001193805-26-001130 Size: 589 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Elon Musk Says mRNA Has ‘Tremendous’ Potential After Moderna, Merck Cancer Vaccine Breakthrough — MRNA Stock Falls Over 11% in Premarket (UPDATED)

Elon Musk said mRNA could fundamentally change disease treatment, turning medicine into a software problem.